Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Govt to Tap R&D Tax Credit System to Push Research on Pediatric Use, Superbug Fight
The government plans to incorporate research on unmet medical needs, such as pediatric drug use and antimicrobial resistance, into the scope of programs subject to the “open innovation” R&D tax credit scheme with an eye on the planned amendment of…
To read the full story
Related Article
- LDP Draws Up Tax Reform Outline, Revamps Credits for R&D Expenses
December 17, 2018
- R&D Tax Credit Refit Taking Shape; Open Innovation Scheme Likely to Cover Research Commissioned to Big Firms
December 10, 2018
- LDP Lawmakers Push for Expansion of R&D Tax Credit
November 30, 2018
- FY2019 Tax Reform Debate Going into Full Swing; Will Pharma Industry Win Expansion in R&D Credit?
November 7, 2018
- MHLW, METI Seek 3-Year Extension for Temporary R&D Tax Credit Measures
September 3, 2018
REGULATORY
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…